Phase I/II Study of AZD2962, an IRAK4 inhibitor, in Hematologic Neoplasms

This open-label, multicentre trial evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD2962—an IRAK4 inhibitor—administered as monotherapy in a dose-escalation design and in combination with other agents. It enrolls patients with myelodysplastic syndromes (MDS) or dysplastic chronic myelomonocytic leukemia (CMML) who are relapsed/refractory or lack standard options, and is sponsored by AstraZeneca.